CA Patent

CA2958110A1 — Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist

Assigned to Vivus LLC · Expires 2016-02-18 · 10y expired

What this patent protects

This invention relates generally to methods and pharmaceutical formulations useful in treating patients suffering from sleep apnea, including obstructive sleep apnea syndrome (OSAS). Treatment is effected by administering a carbonic anhydrase inhibitor to the patient in combinati…

USPTO Abstract

This invention relates generally to methods and pharmaceutical formulations useful in treating patients suffering from sleep apnea, including obstructive sleep apnea syndrome (OSAS). Treatment is effected by administering a carbonic anhydrase inhibitor to the patient in combination with an aldosterone antagonist. Formulations containing a therapeutically effective amount of a carbonic anhydrase inhibitor and a therapeutically effective amount of an aldosterone antagonist are provided as well.

Drugs covered by this patent

Patent Metadata

Patent number
CA2958110A1
Jurisdiction
CA
Classification
—
Expires
2016-02-18
Drug substance claim
No
Drug product claim
No
Assignee
Vivus LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.